Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

ATM germline pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Sarah Elitzur, Ruth Shiloh, Jan L.C. Loeffen, Agata Pastorczak, MD, PhD, Masatoshi Takagi, Simon Bomken, André Baruchel, Thomas Lehrnbecher, Sarah K Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla-Pozza, Stéphane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Verena Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane H Miller, Vassilios Papadakis, MD PhD, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amorós, Anna Zofia Wakuliñska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, Alexander Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Véronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt

Blood blood.2024024283.

https://doi.org/10.1182/blood.2024024283

Published: 2024

Includes: Supplemental data

Journal Articles

NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patients

Blood blood.2023023754.

https://doi.org/10.1182/blood.2023023754

Published: 2024

Includes: Supplemental data

Journal Articles

Genomic imbalances analysis provides new insight into prognostic factors in adult and pediatric T-ALL

Blood blood.2023022154.

https://doi.org/10.1182/blood.2023022154

Published: 2024

Includes: Supplemental data

Journal Articles

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Sarah Elitzur, Ruth Shiloh, Jan Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Stephane Ducassou, Nizar Mahlaoui, Marion Strullu, Thomas Lehrnbecher, Kjeld Schmiegelow, Oussama Abla, Liliia Anderzhanova, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Francesco Ceppi, Nicole Bodmer, Triantafyllia Brozou, Luciano Dalla-Pozza, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Sarah K. Tasian, Thai Hoa Tran, Marek Ussowicz, Jose Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Ronit Nirel, Veronique Minard-Colin, Andishe Attarbaschi, Arndt Borkhardt

Blood (2023) 142 (Supplement 1): 520.

https://doi.org/10.1182/blood-2023-179333

Published: 2023

Journal Articles

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Blood (2023) 142 (Supplement 1): 844.

https://doi.org/10.1182/blood-2023-179298

Published: 2023

Journal Articles

Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

Blood (2023) 142 (Supplement 1): 2980.

https://doi.org/10.1182/blood-2023-185831

Published: 2023

Journal Articles

Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy

Blood (2023) 142 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2023-175045

Published: 2023

Journal Articles

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Patrice Chevallier, Hongtao Liu, Gary J. Schiller, Jean-Baptiste Méar, Daniel J. DeAngelo, Kevin J Curran, Stephan Grupp, Andre Baruchel, Marie Balsat, Alexandra LaCroce, Caroline Roudet, Ana B. Korngold, Kathryn J. Newhall, Eric Laille, Daniel J. Lee, Mark G. Frattini, Richard A. Larson, Nicolas Boissel

Blood (2023) 142 (Supplement 1): 4847.

https://doi.org/10.1182/blood-2023-187252

Published: 2023

Journal Articles

Chronic Graft-Versus-Host Disease in Long-Term Survivors of Childhood Leukemia

Blood (2023) 142 (Supplement 1): 3762.

https://doi.org/10.1182/blood-2023-178121

Published: 2023

Journal Articles

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Amelie Polutta, Dirk Reinhardt, Andre Baruchel, Henrik Hasle, Franco Locatelli, C. Michel Zwaan, Michael Frühwald, Silke Westphal, Michael Dworzak, Heidrun Boztug, Gabriele Escherich, Thomas Lehrnbecher, Bianca F. Goemans, Brigitte Strahm, Markus Schneider, Lina Hoffmeister, Katharina Waack

Blood (2023) 142 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2023-180820

Published: 2023

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Blood (2023) 142 (Supplement 1): 730.

https://doi.org/10.1182/blood-2023-181593

Published: 2023

Journal Articles

Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML

Frederic Millot, Joe De Keizer, Markus Metzler, Meinolf Suttorp, Petr Sedlacek, Maaike Luesink, Frankie WT Cheng, Krzysztof Kalwak, Birgitte Lausen, Gordana Jakovljevic, Barbara De Moerloose, Michael Dworzak, Marina Borisevich, Julia Yajima, Mirella Ampatzidou, Roula Farah, Emilia Kaiserova, Adalet Meral Günes, Andre Baruchel

Blood (2023) 142 (Supplement 1): 448.

https://doi.org/10.1182/blood-2023-173810

Published: 2023

Journal Articles

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Blood (2023) 141 (11): 1353–1358.

https://doi.org/10.1182/blood.2022017755

Published: 2023

Includes: Supplemental data

Journal Articles

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Blood (2023) 141 (7): 743–755.

https://doi.org/10.1182/blood.2022016975

Published: 2023

Includes: Supplemental data

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

Blood (2022) 140 (Supplement 1): 2187–2189.

https://doi.org/10.1182/blood-2022-157345

Published: 2022

Journal Articles

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Blood (2022) 139 (12): 1785–1793.

https://doi.org/10.1182/blood.2021012328

Published: 2022

Includes: Supplemental data

Journal Articles

Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis

Blood (2021) 138 (Supplement 1): 516.

https://doi.org/10.1182/blood-2021-150272

Published: 2021

Journal Articles

Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia: Why Do Adolescents and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Blood (2021) 138 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2021-146769

Published: 2021

NARROW

ATM germline pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patients

Genomic imbalances analysis provides new insight into prognostic factors in adult and pediatric T-ALL

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Chronic Graft-Versus-Host Disease in Long-Term Survivors of Childhood Leukemia

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis

Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia: Why Do Adolescents and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only